<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Febuxostat improves outcome in a rat model of cancer cachexia</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-04-21">21 April 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Masaaki</forename><surname>Konishi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Innovative Clinical Trials</orgName>
								<orgName type="department" key="dep2">Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University Medical Centre Göttingen</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Loes</forename><surname>Pelgrim</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="laboratory">Applied Cachexia Research</orgName>
								<orgName type="institution">Charité Medical School</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">Radboud University Nijmegen</orgName>
								<address>
									<settlement>Nijmegen</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anika</forename><surname>Tschirner</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="laboratory">Applied Cachexia Research</orgName>
								<orgName type="institution">Charité Medical School</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anna</forename><surname>Baumgarten</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="laboratory">Applied Cachexia Research</orgName>
								<orgName type="institution">Charité Medical School</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephan</forename><surname>Von Haehling</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Innovative Clinical Trials</orgName>
								<orgName type="department" key="dep2">Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University Medical Centre Göttingen</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University Medical Centre Göttingen</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sandra</forename><surname>Palus</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Innovative Clinical Trials</orgName>
								<orgName type="department" key="dep2">Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University Medical Centre Göttingen</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wolfram</forename><surname>Doehner</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Center for Stroke Research Berlin</orgName>
								<orgName type="institution">Charité Medical School</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Innovative Clinical Trials</orgName>
								<orgName type="department" key="dep2">Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University Medical Centre Göttingen</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jochen</forename><surname>Springer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Innovative Clinical Trials</orgName>
								<orgName type="department" key="dep2">Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University Medical Centre Göttingen</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University Medical Centre Göttingen</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Department of Innovative Clinical Trials</orgName>
								<orgName type="institution">University Medical Centre Göttingen</orgName>
								<address>
									<addrLine>Robert-Koch-Str. 40</addrLine>
									<postCode>37075</postCode>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Febuxostat improves outcome in a rat model of cancer cachexia</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-04-21">21 April 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">5FE7CD2BA6F0C125E601B6CEBB709EDF</idno>
					<idno type="DOI">10.1002/jcsm.12017</idno>
					<note type="submission">Received: 7 November 2014; Revised: 16 January 2015; Accepted: 24 February 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:20+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Cancer cachexia</term>
					<term>Yoshida hepatoma animal model</term>
					<term>Weight loss</term>
					<term>Wasting</term>
					<term>Survival</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background Activity of xanthine oxidase is induced in cancer cachexia, and its inhibition by allopurinol or oxypurinol improves survival and reduces wasting in the Yoshida hepatoma cancer cachexia model.</s><s>Here, we tested the effects of the second-generation xanthine oxidase inhibitor febuxostat compared with placebo in the same model as used previously by our group.</s></p><p><s>Methods Wistar rats (~200 g) were treated daily with febuxostat at 5 mg/kg/day or placebo via gavage for a maximum of 17 days.</s><s>Weight change, quality of life, and body composition were analysed.</s><s>After sacrifice, proteasome activity in the gastrocnemius muscle was measured.</s><s>Muscle-specific proteins involved in metabolism were analysed by western blotting.</s></p><p><s>Results Treatment of the tumour-bearing rats with febuxostat led to a significantly improved survival compared with placebo (hazard ratio: 0.45, 95% confidence interval: 0.22-0.93,</s><s>P = 0.03).</s><s>Loss of body weight was reduced (À26.3</s><s>± 12.4 g) compared with placebo (À50.2 ± 2.1 g, P &lt; 0.01).</s><s>Wasting of lean mass was attenuated (À12.7 ± 10.8 g) vs. placebo (À31.9 ± 2.1 g, P &lt; 0.05).</s><s>While we did not see an effect of febuxostat on proteasome activity at the end of the study, the pAkt/Akt ratio was improved by febuxostat (0.94 ± 0.09) vs. placebo (0.41 ± 0.05, P &lt; 0.01), suggesting an increase in protein synthesis.</s></p><p><s>Conclusions Febuxostat attenuated cachexia progression and improved survival of tumour-bearing rats.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Cachexia is frequently observed in chronic illnesses such as cancer, heart failure, and chronic obstructive pulmonary disease <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref> and is characterized by weight loss of at least 5% as a consequence of hypercatabolism with or without impaired feeding.</s><s>Cachexia is a common complication in patients with advanced cancer and accounts for up to 30% of cancer deaths. <ref type="bibr" target="#b1">2</ref> Taken together, effective treatment for cancer cachexia is considered a great unmet medical need. <ref type="bibr" target="#b2">3</ref></s><s>yperuricaemia, which is often observed in cancer patients regardless of tumour lysis syndrome, <ref type="bibr" target="#b3">4</ref> has been reported as a negative prognostic factor in terminally ill cancer patients. <ref type="bibr" target="#b4">5</ref></s><s>The increased uric acid levels reflect higher xanthine oxidase (XO) enzymatic activity, which also results in an increased generation of reactive oxygen species (ROS). <ref type="bibr" target="#b5">6</ref></s><s>ROS in turn plays an important role in wasting by activation of calcium-activated protease, caspase, and proteasome system. <ref type="bibr" target="#b6">7</ref></s><s>We have previously shown that the inhibition of XO by allopurinol reduced wasting and improved outcome in a rat model of cancer cachexia. <ref type="bibr" target="#b7">8</ref></s><s>lthough allopurinol is a commonly used XO inhibitor for the treatment of hyperuricaemia and has generally acceptable efficacy and safety profiles, rare but severe adverse reactions have been also reported. <ref type="bibr" target="#b8">9</ref></s><s>Febuxostat is a novel non-purine selective XO inhibitor <ref type="bibr" target="#b9">10</ref> and could be a better alternative to allopurinol. <ref type="bibr" target="#b10">11</ref></s><s>The purpose of this study is to assess the effect of febuxostat on survival, body weight, and body composition using the Yoshida hepatoma model.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design</head><p><s>Juvenile Wistar Han rats aged 7 weeks (weight ~200 g) were housed in our Specific Pathogen Free (SPF)-animal facility at a constant temperature of 22°C and exposed to a 12 h light cycle.</s><s>On Day 1, rats were inoculated with 10 8 growing Yoshida hepatoma AH-130 cells <ref type="bibr" target="#b11">12</ref> into the peritoneum.</s><s>Before tumour inoculation, baseline weight and body composition were assessed.</s><s>Rats were randomized to placebo (n = 56) or 5 mg/kg/day febuxostat (n = 23).</s><s>Treatment with febuxostat or placebo was given via gavage daily.</s><s>Febuxostat was obtained from Tocris Bioscience (Wiesbaden, Germany).</s><s>Eleven rats on placebo and seven on febuxostat were scheduled to be sacrificed on Day 11 for the early assessment; the remaining 45 animals on placebo and 16 on febuxostat were analysed for survival, defined as reaching ethical endpoints for euthanasia (apathy, reduced body temperature, and disturbed blood flow). <ref type="bibr" target="#b7">8</ref></s><s>Additionally, 10 rats were injected with saline (=sham), treated by placebo, and used as a reference.</s><s>Body composition and weight were recorded after removal of the tumour on Day 11, Day 17, or the respective days of killing, if rats had to be euthanized earlier owing to reaching ethical endpoints.</s><s>Weight of tissue and organs was recorded, and tumour cells were counted using a Neubauer chamber.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Body composition</head><p><s>Body composition (fat and lean body mass) was analysed with a nuclear magnetic resonance spectroscopy device EchoMRI-700TM (Echo Medical Systems, Houston, TX, USA) as described before. <ref type="bibr" target="#b12">13</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quality-of-life indicators</head><p><s>Spontaneous movement and food intake were recorded as indicators of quality of life.</s><s>Animals were housed individually, and their activity was measured by an infrared monitoring system (Supermex, Muromachi, Tokyo, Japan) over a 24 h period as described previously. <ref type="bibr" target="#b13">14</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Echocardiography</head><p><s>Echocardiography using the high-resolution Veno770 system (Visual Sonics, Toronto, Canada) was performed as described previously. <ref type="bibr" target="#b14">15</ref></s><s>Briefly, rats were anaesthetized with 1.5% isoflurane and laid in a supine position on a heated surface to maintain body temperature, and hair was removed from the left chest.</s><s>Recordings were made in B-mode and M-mode to calculate functional parameters and measure cardiac function and dimensions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Proteasome activity</head><p><s>Proteasome activity was analysed as described previously. <ref type="bibr" target="#b15">16</ref></s><s>riefly, the gastrocnemius muscle was homogenized in an ice-cold buffer.</s><s>Protein was incubated with fluorogenic substrates (benzyloxycarbonyl-Leu-Leu-Glu-7-amido-4-methylcoumarin for trypsin-like activity, succinyl-Leu-Leu-Val-Try-7amido-4-methylcoumarin for chymotrypsin-like activity and benzoyl-Val-Gly-Arg-7-amidocoumarin for peptidyl-glutamyl protein-hydrolysing activity, Biomol, Hamburg, Germany).</s><s>The fluorescence intensity was measured with a fluorometer (Twinkle LB 970, Berthold, Bad Wildbad, Germany) at 360 and 460 nm emission.</s><s>The activity, expressed as nanomole per milligramme per minute, was calculated by using free amidomethylcoumarin as a working standard.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Caspase activity</head><p><s>Caspase-3 and caspase-6 activities were analysed as described previously. <ref type="bibr" target="#b15">16</ref></s><s>Briefly, the gastrocnemius muscle was homogenized in ice-cold buffer.</s><s>The homogenate was frozen on dry ice/ethanol and heated to 37°C for three cycles.</s><s>After centrifugation (20 000 g for 30 min), 100 μg protein was pre-incubated in assay buffer (100 mM 4-(2-hydroxyethyl)-1-piperanzineethanesulfonic acid (HEPES) pH 7.5, 10% sucrose, 0.1% 3-(3-cholamidepropyl) dimethylammonio-1-propanesulphonate (CHAPS), 2% dimethyl sulphoxide (DMSO), and 10 mM dithiothreitol (DTT) with or without 50 μM caspase-3 or caspase-6 inhibitor Ac-DEVD-CHO or Ac-VEID-CHO) at 37°C for 30 min.</s><s>The fluorogenic substrate (50 μM) Ac-DEVD-AMC or Ac-VEID-AMC was added for caspase-3 and caspase-6.</s><s>Assay conditions were identical to proteasome assay.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Western blotting</head><p><s>Protein lysates were prepared from the gastrocnemius muscle according to standard protocols.</s><s>We used primary antibodies against Akt (9272), pAkt (Ser473; 4051), pAkt (Thr308; 9275), p-p70S6K (Thr389; 9025), 4E-BP1 (53H11; 9644), p4E-BP1 (Ser65; 9451), and p4E-BP1 (Thr 37/47; 9459), all from Cell Signaling, and p70S6K (sc-230; Santa Cruz), as well as appropriate secondary antibodies.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistics</head><p><s>Data were analysed with GraphPad PRISM 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). <ref type="bibr" target="#b16">17</ref></s><s>Results are shown as mean ± standard error of mean.</s><s>For the comparisons among groups, data were analysed with analysis of variance followed by post hoc comparisons using Tukey's test.</s><s>Survival was assessed by Cox proportional hazard analysis.</s><s>A P-value of &lt;0.05 was considered significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>No treatment effect was observed on tumour growth.</s><s>On Day 11, total tumour cell numbers were 4.63 ± 0.39 × 10 9 in the placebo-treated rats and 4.04 ± 0.28 × 10 9 cells in rats with febuxostat (P &gt; 0.4).</s><s>At the end of the study, total tumour cell numbers were 4.20 ± 0.29 × 10 9 cells in the placebo-treated rats and 4.19 ± 0.40 × 10 9 cells in rats with febuxostat (P &gt; 0.9).</s><s>There were no observations of other malignancies during necropsy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Body weight and body composition</head><p><s>Average loss of body weight from baseline to the end of study was higher in the placebo group than in treated rats (À50.2 ± 2.1 g vs. À26.3</s><s>± 12.4 g, P &lt; 0.01; Figure <ref type="figure" target="#fig_0">1A</ref>).</s><s>The loss of lean and fat mass was also higher in the placebo group than in treated rats (À31.0 ± 2.4 g vs. À12.7 ± 10.8 g, P &lt; 0.05 for lean mass and À12.8 ± 0.5 g vs. À9.1 ± 1.8 g, P &lt; 0.05 for fat mass, Figure <ref type="figure" target="#fig_0">1B and C</ref>).</s><s>No significant difference was observed between the two groups on Day 11.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Organ weights</head><p><s>Organ weights on Day 11 and the end of study are shown in Table <ref type="table" target="#tab_0">1</ref>.</s><s>The weights of the heart, liver, kidney, gastrocnemius, and tibialis were comparable among tumour-bearing rats regardless of their treatment and study length.</s><s>At the end of study, the weights of the spleen, white adipose tissue, extensor digitalis longus, and soleus were higher in febuxostat than in placebo group.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quality of life</head><p><s>Change in food intake was 5.1 ± 0.9 g/day in sham and reduced in both the placebo (À14.0 ± 0.8, P &lt; 0.001 vs. sham) and febuxostat (À10.0 ± 2.1, P &lt; 0.001 vs. sham) groups.</s><s>There was no significant difference between the placebo and febuxostat groups.</s><s>Change in locomotor activity was À2619 ± 3453 counts/day in sham and also reduced in both the placebo (À39 054 ± 2119, P &lt; 0.001 vs. sham) and febuxostat (À30 693 ± 5432, P &lt; 0.01 vs. sham) groups.</s><s>There was no significant difference between the placebo and febuxostat groups.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Echocardiography</head><p><s>Echocardiographic parameters are shown in Figure <ref type="figure" target="#fig_1">2</ref>. The declines in left ventricular mass in 11 days were more pronounced in placebo-treated rats than febuxostat-treated rats (À81.2 ± 10.3 vs. À3.4 ± 27.8 mg, respectively, P &lt; 0.01, Figure <ref type="figure" target="#fig_1">2A</ref>).</s><s>Changes to baseline in left ventricular contraction, diameter, wall thickness, and stroke volume were comparable between the two groups (Figure <ref type="figure" target="#fig_1">2B-H</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Catabolic and anabolic signalling</head><p><s>Catabolic and anabolic signalling are shown in Figure <ref type="figure">3</ref>. On Day 11, trypsin-like proteasome activity was significantly lower in febuxostat-treated rats than in placebo-treated rats (305.7 ± 35.6 vs. 527.2</s><s>± 70.7 nmol/mg/min, respectively, P &lt; 0.01).</s><s>Chymotrypsin-like activity, peptidyl-glutamyl protein-hydrolyzing activity, and the activities of caspase-3 and caspase-6 were comparable between both groups on Day 11 and at the end of study.</s><s>The phosphorylation of the Ser 473 site in Akt was increased both on Day 11 (the pAkt/Akt ratio; 1.84 ± 0.23 in febuxostat vs. 0.41 ± 0.05 in placebo, P &lt; 0.001) and at the end of study (0.94 ± 0.09 in febuxostat, P &lt; 0.01).</s><s>The phosphorylation of the Thr 308 site in Akt was increased on Day 11 (0.89 ± 0.14 in febuxostat vs. 0.26 ± 0.05 in placebo, P &lt; 0.01).</s><s>However, its downstream target p70 S6K and 4E-BP1 phosphorylation were comparable between both groups.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Survival</head><p><s>On Day 17, the overall survival was 20% in the placebo group and 59% in the febuxostat group (Figure <ref type="figure" target="#fig_2">4</ref>).</s><s>The median survival was 14 days in the placebo group and 17 days in the febuxostat group.</s><s>Treatment with febuxostat significantly reduced mortality (hazard ratio: 0.45; 95% confidence interval: 0.22-0.93;</s><s>P = 0.03).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>In the present study, treatment of tumour-bearing rats with febuxostat led to a significantly improved survival compared with placebo.</s><s>Loss of body weight and wasting of lean/fat mass were attenuated in treated animals vs. placebo.</s><s>No effect on food intake and locomotor activity was observed.</s></p><p><s>Figure <ref type="figure">3</ref> Catabolic and anabolic signalling in the gastrocnemius muscle: on Day 11, trypsin-like proteasome activity was significantly lower in febuxostat-treated rats than in placebo-treated rats (P &lt; 0.01).</s><s>Chymotrypsin-like, peptidyl-glutamyl protein-hydrolyzing (PGPH), caspase-3, and caspase-6 activities were comparable between both groups both on Day 11 and at the end of study.</s><s>The phosphorylation of the Ser 473 site in Akt was increased both on Day 11 (P &lt; 0.001 vs. placebo) and at the end of study (P &lt; 0.01 vs. placebo).</s><s>The phosphorylation of the Thr 308 site in Akt was increased on Day 11 (P &lt; 0.01 vs. placebo).</s><s>However, its downstream target p70 S6K and 4E-BP1 phosphorylation were comparable between both groups.</s><s>**P &lt; 0.01, ***P &lt; 0.001 vs. placebo day 11.</s><s>While we did not see an effect of febuxostat on the proteasome activity at the end of the study, the pAkt/Akt ratio was improved by febuxostat vs. placebo, suggesting an increase in protein synthesis.</s></p><p><s>The main finding of the present study is attenuated weight loss and the improved survival in animals treated with febuxostat.</s><s>The primary underlying mechanism would be XO inhibition.</s><s>We have previously shown the increased XOdependent ROS production in the same rat model as the present study and that XO inhibition by allopurinol and oxypurinol drastically reduced ROS. <ref type="bibr" target="#b7">8</ref></s><s>In addition, ROS reduction may lead to reduced catabolic signalling such as the ubiquitin-proteasome pathway through inflammatory transcription factors and attenuate wasting. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b17">18</ref></s><s>Also in the present study, reduced proteasome activity was indicated by the fact that trypsin-like activity in gastrocnemius muscle was significantly reduced on Day 11 in febuxostat-treated rats.</s><s>On the other hand, enhanced anabolic signalling was also shown by significantly increased Akt phosphorylation in febuxostattreated rats.</s><s>It may be explained by the hypothesis that ROS-induced reduction in Akt protein <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b19">20</ref> would be reversed by febuxostat.</s><s>In a previous study, however, febuxostat did not affect myocardial Akt phosphorylation in a heart failure model. <ref type="bibr" target="#b20">21</ref></s><s>lthough allopurinol is known to be a safe and effective XO inhibitor, serious adverse reactions such as allopurinol hypersensitivity syndromes have also been reported. <ref type="bibr" target="#b8">9</ref></s><s>Given that accumulation or metabolic actions of allopurinol and its metabolites might account for such adverse reactions especially in patients with renal dysfunction, it might be of importance to note that febuxostat is mainly metabolized in the liver. <ref type="bibr" target="#b9">10</ref></s><s>In addition, febuxostat might be able to attenuate ROS more effectively than allopurinol because allopurinol, but not febuxostat, might induce a resistance to inhibition in XO and undesirable production of superoxide. <ref type="bibr" target="#b21">22</ref></s><s>As a result, the mortality of febuxostat-treated animals was significantly lower than placebo-treated animals in the present study.</s><s>To the best of our knowledge, there is only one study referring to the effect of febuxostat on survival, which indicated no survival benefit in a left ventricular hypertrophy mice model. <ref type="bibr" target="#b20">21</ref></s><s>There are also some experimental studies about non-hypouricaemic effect by febuxostat, which includes improved endothelial function <ref type="bibr" target="#b22">23</ref> or left ventricular performance, <ref type="bibr" target="#b23">24</ref> reduced intracellular ROS production, <ref type="bibr" target="#b24">25</ref> and no effect on blood pressure. <ref type="bibr" target="#b25">26</ref></s><s>In some clinical trial using febuxostat for hyperuricaemia, reduction in inflammatory signal (tumour necrosis factor-α) or oxidative stress was observed. <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b27">28</ref></s><s>ogether with our previous reports, febuxostat as well as allopurinol or oxypurinol would be candidates for the treatment drugs for cachexia.</s></p><p><s>We also assessed the effect of febuxostat on cardiac function by echocardiography.</s><s>On Day 11, loss of left ventricular mass was significantly reduced in febuxostat, indicating attenuated cardiac wasting in cancer cachexia, which was also demonstrated in our previous study by oxypurinol. <ref type="bibr" target="#b29">29</ref></s><s>However, the effect by febuxostat in left ventricular ejection fraction did not reach statistical significance despite previously reported improvement in ejection fraction by oxypurinol. <ref type="bibr" target="#b29">29</ref></s><s>lthough little is known about the consequences of wasting on cardiac function <ref type="bibr" target="#b30">30</ref> and whether it leads to heart failure or impaired survival, some of the drugs used in heart failure treatment would be effective in our previous study. <ref type="bibr" target="#b15">16</ref></s><s>As febuxostat was also reported to be effective in mouse and dog models of heart failure, <ref type="bibr" target="#b20">21,</ref><ref type="bibr" target="#b23">24</ref> the survival effect in the present study could be influenced by the effect on the heart to some extent.</s></p><p><s>The Yoshida hepatoma model is a well-established cancer cachexia model and known to have a high mortality rate without treatment.</s><s>Its high mortality was also shown in our previous studies, <ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b31">31</ref> which are in accordance with the results of this study.</s><s>The dose of febuxostat (5 mg/kg/day) was as appropriate as that used in diabetic rats model <ref type="bibr" target="#b22">23</ref> or mice models of heart failure. <ref type="bibr" target="#b20">21</ref></s><s>here are also some limitations in the present study.</s><s>We did not measure inflammation and ROS, although we had found a significant reduction in interleukin-6 and tumour necrosis factor-α expression and reduced ROS production by allopurinol and oxypurinol. <ref type="bibr" target="#b7">8</ref></s><s>The mechanisms under up-regulated anabolic signal, especially those in the downstream of Akt, were not elucidated precisely in this study, where some of such signals (p70 S6K and 4E-BP1s phosphorylation <ref type="bibr" target="#b32">32</ref> ) were not up-regulated significantly.</s><s>The lack of information about catabolic pathways other than proteasome/caspase activity is also a limitation.</s></p><p><s>In conclusion, the present study demonstrated that treatment with febuxostat improved survival and attenuated the loss of lean and fat mass in the Yoshida hepatoma rat model of cancer cachexia.</s><s>The improvement in protein synthesis suggested by enhanced phosphorylation in Akt was also observed and might underlie the beneficial effect of febuxostat.</s><s>Our data suggest that febuxostat might be a candidate for the treatment drug for cancer cachexia, and clinical studies are warranted.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 Change in body weight (A), lean body mass (B), and fat mass (C): average loss of body weight, lean mass, and fat mass were higher in the placebo group than in treated rats at the end of study (P &lt; 0.01 for body weight, P &lt; 0.05 for lean mass, and P &lt; 0.05 for fat mass).</s><s>No significant difference was observed between both groups on Day 11. ***P &lt; 0.001 vs. placebo Day 11. #P &lt; 0.05, ##P &lt; 0.01 vs. placebo final.</s></p></div></figDesc><graphic coords="3,140.03,476.39,313.87,228.70" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 Echocardiography: the declines in left ventricular (LV) mass (A) in 11 days were more remarkable in placebo-treated rats than in febuxostat-treated rats (P &lt; 0.01).</s><s>Changes in left ventricular contraction (B, C, and F), diameter (D and E), wall thickness (G), and heart rate (H) were comparable between both groups.</s><s>**P &lt; 0.01, ***P &lt; 0.001 vs. placebo Day 11.</s></p></div></figDesc><graphic coords="4,84.02,391.30,425.95,313.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 4</head><label>4</label><figDesc><div><p><s>Figure 4 Kaplan-Meier survival curves: febuxostat reduced mortality compared with placebo.</s></p></div></figDesc><graphic coords="5,303.25,583.82,235.36,121.27" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Organ and tissue weights at Day 11 and the end of study</s></p></div></figDesc><table><row><cell></cell><cell>Sham</cell><cell>Placebo Day</cell><cell>Febuxostat</cell><cell>Placebo final</cell><cell>Febuxostat final</cell></row><row><cell>Organ weight (mg)</cell><cell>(n = 10)</cell><cell>11 (n = 11)</cell><cell>Day 11 (n = 7)</cell><cell>(n = 45)</cell><cell>(n = 16)</cell></row><row><cell>Heart</cell><cell>893 ± 41**</cell><cell>636 ± 17</cell><cell>543 ± 15</cell><cell>553 ± 15</cell><cell>587 ± 29</cell></row><row><cell>Liver</cell><cell>11 292 ± 511**</cell><cell>7 480 ± 232</cell><cell>6 775 ± 359</cell><cell>5 640 ± 151</cell><cell>6 378 ± 675</cell></row><row><cell>Spleen</cell><cell>632 ± 32**</cell><cell>278 ± 29</cell><cell>302 ± 39</cell><cell>159 ± 8*</cell><cell>253 ± 44***</cell></row><row><cell>Kidney left</cell><cell>1 036 ± 26**</cell><cell>728 ± 18</cell><cell>692 ± 37</cell><cell>705 ± 18</cell><cell>752 ± 36</cell></row><row><cell>White adipose tissue</cell><cell>1 282 ± 173**</cell><cell>203 ± 85</cell><cell>136 ± 70</cell><cell>48 ± 28</cell><cell>501 ± 221***</cell></row><row><cell>Brown adipose tissue</cell><cell>311 ± 43**</cell><cell>100 ± 19</cell><cell>116 ± 15</cell><cell>95 ± 5</cell><cell>139 ± 16</cell></row><row><cell>Musculus gastrocnemius</cell><cell>1 426 ± 27**</cell><cell>953 ± 30</cell><cell>874 ± 51</cell><cell>795 ± 20</cell><cell>911 ± 83</cell></row><row><cell>Musculus tibialis</cell><cell>501 ± 7**</cell><cell>315 ± 14</cell><cell>318 ± 19</cell><cell>280 ± 7</cell><cell>312 ± 32</cell></row><row><cell>Musculus extensor digitalis longus</cell><cell>115 ± 6**</cell><cell>80 ± 4</cell><cell>77 ± 4</cell><cell>68 ± 1</cell><cell>83 ± 8***</cell></row><row><cell>Musculus soleus</cell><cell>121 ± 6*</cell><cell>91 ± 4</cell><cell>85 ± 5</cell><cell>76 ± 2</cell><cell>91 ± 7***</cell></row><row><cell cols="4">*P &lt; 0.01 vs. placebo Day 11; **P &lt; 0.001 vs. placebo Day 11; ***P &lt; 0.05 vs. placebo final.</cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Journal of Cachexia, Sarcopenia and Muscle 2015; 6: 174-180 DOI: 10.1002/jcsm.12017</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acknowledgements M.K. was supported by the Sumitomo Life Welfare and Culture Foundation operating grant as a long-term overseas research fellow.</s><s>The authors have read and certified that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia, and Muscle.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of Interest</head><p><s>None declared.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Cachexia: a new definition</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Argiles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bales</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Baracos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Guttridge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="793" to="799" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Cachexia as a major public health problem: frequent, costly, and deadly</title>
		<author>
			<persName><forename type="first">J</forename><surname>Farkas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kalantar-Zadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lainscak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="173" to="178" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Cachexia vs obesity: where is the real unmet clinical need?</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="245" to="246" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hammarsten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hogstedt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood Press</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="47" to="55" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Uric acid as a prognostic factor for survival time: a prospective cohort study of terminally ill cancer patients</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Shim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Suh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pain Symptom Manage</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="493" to="501" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Hypoxia injures endothelial cells by increasing endogenous xanthine oxidase activity</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Terada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Guidot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Leff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">R</forename><surname>Willingham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Hanley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Piermattei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="3362" to="3366" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Mechanisms of disuse muscle atrophy: role of oxidative stress</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Powers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Kavazis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Deruisseau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Regul Integr Comp Physiol</title>
		<imprint>
			<biblScope unit="volume">288</biblScope>
			<biblScope unit="page" from="R337" to="R344" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia</title>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tschirner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hartman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Palus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Wirth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Ruis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="2187" to="2196" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Allopurinol hypersensitivity syndrome: a review</title>
		<author>
			<persName><forename type="first">F</forename><surname>Arellano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Sacristan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Pharmacother</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="337" to="343" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Takano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hase-Aoki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Horiuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kasahara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kondo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Life Sci</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="1835" to="1847" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Febuxostat compared with allopurinol in patients with hyperuricemia and gout</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Schumacher</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Wortmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Macdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Eustace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Palo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page" from="2450" to="2461" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model</title>
		<author>
			<persName><forename type="first">P</forename><surname>Costelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Carbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tessitore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Bagby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Lopez-Soriano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Argiles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="2783" to="2789" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Longitudinal changes in total body creatine pool size and skeletal muscle mass using the D-creatine dilution method</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Stimpson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Leonard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Clifton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Poole</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Shearer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="217" to="223" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Ursodeoxycholic acid treatment in a rat model of cancer cachexia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tschirner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Palus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="31" to="36" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Akashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Palus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Datta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Halem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thoene-Reineke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="267" to="275" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Prevention of liver cancer cachexia-induced cardiac wasting and heart failure</title>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tschirner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Haghikia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Grzesiak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="932" to="941" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model</title>
		<author>
			<persName><forename type="first">K</forename><surname>Lenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Palus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Datta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Culler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="63" to="69" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Molecular and cellular mechanisms of skeletal muscle atrophy: an update</title>
		<author>
			<persName><forename type="first">A</forename><surname>Fanzani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Conraads</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Penna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Martinet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="163" to="179" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Akt/protein kinase B in skeletal muscle physiology and pathology</title>
		<author>
			<persName><forename type="first">M</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Falasca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Blough</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Physiol</title>
		<imprint>
			<biblScope unit="volume">226</biblScope>
			<biblScope unit="page" from="29" to="36" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Ceramide and reactive oxygen species generated by H 2 O 2 induce caspase-3-independent degradation of Akt/protein kinase B</title>
		<author>
			<persName><forename type="first">D</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Salinas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Fujita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tsuruo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cuadrado</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">277</biblScope>
			<biblScope unit="page" from="42943" to="42952" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Xanthine oxidase inhibition with febuxostat attenuates systolic overloadinduced left ventricular hypertrophy and dysfunction in mice</title>
		<author>
			<persName><forename type="first">X</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Wessale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Card Fail</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="746" to="753" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">Z</forename><surname>Malik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Hundley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Romero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Radi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Freeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Tarpey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Free Radic Biol Med</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="179" to="184" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Febuxostat contributes to improvement of endothelial dysfunction in an experimental model of streptozocininduced diabetic rats</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Woo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">171</biblScope>
			<biblScope unit="page" from="e110" to="e112" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Acute effects of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in pacing induced heart failure</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Bache</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cardiovasc Pharmacol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="255" to="263" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK</title>
		<author>
			<persName><forename type="first">J</forename><surname>Nomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Busso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ives</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tsujimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>So</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e75527</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive rats</title>
		<author>
			<persName><forename type="first">T</forename><surname>Szasz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Garver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Burnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Fink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Watts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e56046</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sezai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Soma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Yoshitake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wakui</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ J</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="2043" to="2049" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title level="m" type="main">As compared to allopurinol, uratelowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Tausche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Christoph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Forkmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Richter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kopprasch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bielitz</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Rheumatol Int</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="101" to="109" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">The xanthine oxidase inhibitor oxypurinol reduces cancer cachexiainduced cardiomyopathy</title>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tschirner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hartman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="page" from="3527" to="3531" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Research on cachexia, sarcopenia and skeletal muscle in cardiology</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Coats</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="219" to="223" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia</title>
		<author>
			<persName><forename type="first">K</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Palus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="105" to="109" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass</title>
		<author>
			<persName><forename type="first">K</forename><surname>Sakuma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Yamaguchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="77" to="94" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
